SCHEMBL5605709

SCHEMBL5605709

CCOC(=O)C1CCN(C(=O)CCl)CC1

nearest known ligand 0.66

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.66
▸ MAPT P10636 2/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ POLB P06746 1/20 0.62
▸ HTT P42858 1/20 0.62
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ TSHR P16473 1/20 0.57
▸ HSD17B10 Q99714 2/20 0.56
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12297020 0.86 ALDH1A1 (0.69) ALDH1A1MAPTMEN1KMT2ATSHR
SCHEMBL6983366 0.85 ALDH1A1 (0.68) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6983363 0.85 ALDH1A1 (0.68) ALDH1A1MAPTMEN1KMT2ATSHR
SCHEMBL7400389 0.83 ALDH1A1 (0.66) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL10039631 0.83 ALDH1A1 (0.66) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL16809642 0.83 MAPT (0.68) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL22481582 0.83 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2POLBHTTMEN1
SCHEMBL1720494 0.82 MAPT (0.72) ALDH1A1MAPTPOLBHTTMEN1
SCHEMBL2607028 0.82 POLB (0.65) ALDH1A1MAPTSMN1; SMN2POLBMEN1
SCHEMBL5605913 0.82 MAPT (0.69) ALDH1A1MAPTSMN1; SMN2POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3261639-B1 SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS VERSEON INT CORPORATION (US) 2022-08-24 — — EP disclosed
US-20200109132-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS VERSEON INTERNATIONAL CORPORATION 2020-04-09 — — US disclosed
US-20180237421-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS VERSEON INTERNATIONAL CORPORATION 2018-08-23 — — US disclosed
EP-3261639-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS Verseon Corporation (US) 2018-01-03 — — EP disclosed
WO-2016138532-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS VERSEON CORPORATION (US) 2016-09-01 — — WO disclosed
US-7166594-B2 Antibacterial activity AVENTIS PHARMA S.A. (FR) 2007-01-23 — — US disclosed
US-20030149004-A1 Streptogramin derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. 2003-08-07 — — US disclosed
US-6569854-B1 Virginamycins AVENTIS PHARMA S.A. (FR) 2003-05-27 — — US disclosed
US-5681841-A PREVENTION CELL AGGREGATION KARL THOMAE GMBH (DE) 1997-10-28 — — US disclosed
EP-0587134-A2 Cyclic urea derivatives, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1994-03-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109132-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS SPINT2, PRSS1, SERPINE1 ALDH1A1 3372/4885MAPT 2377/4885SMN1; SMN2 3676/4885
US-20180237421-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS SPINT2, PRSS1, SERPINE1 ALDH1A1 3372/4885MAPT 2377/4885SMN1; SMN2 3676/4885
US-20030149004-A1 Streptogramin derivatives, their preparation and compositions containing them MRPL21, ABHD5, APEH ALDH1A1 4296/4885MAPT 4847/4885SMN1; SMN2 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback